Monocarboxylate Transporter
Monocarboxylate transporters (MCTs) constitute a family of proton-linked plasma membrane transporters that carry molecules having one carboxylate group (monocarboxylates), such aslactate and pyruvate, across biological membranes. Highly malignant tumors rely heavily on aerobic glycolysis (metabolism of glucose to lactic acid even under ample tissue oxygen; Warburg Effect) and thus need to efflux lactic acid via MCTs to the tumor micro-environment to maintain a robust glycolytic flux and to prevent the tumor from being "pickled to death". The MCTs have been successfully targeted in pre-clinical studies using RNAi and a small-molecule inhibitor alpha-cyano-4-hydroxycinnamic acid (ACCA; CHC) to show that inhibiting lactic acid efflux is a very effective therapeutic strategy against highly glycolytic malignant tumors.
Monocarboxylate Transporter Isoform Specific Products
All Product Categories
-
Monocarboxylate Transporter Related Products (42)
Related Products (42)
-
Monocarboxylate Transporter Isoform Comparison
-
2-Hydroxy-4-methoxybenzoic acid
0 Images2-Hydroxy-4-methoxybenzoic acid is an orally active inhibitor of MCT-1 and MCT-4, as well as a plant biomarker. 2-Hydroxy-4-methoxybenzoic acid can be isolated from roots. 2-Hydroxy-4-methoxybenzoic acid induces Apoptosis and loss of mitochondrial membrane potential. 2-Hydroxy-4-methoxybenzoic acid exhibits anticancer activity against breast cancer. 2-Hydroxy-4-methoxybenzoic acid normalizes lactic acid levels. 2-Hydroxy-4-methoxybenzoic acid neutralizes viper venom and attenuates its lethal, hemorrhagic, coagulant and anticoagulant activities in male albino mice. 2-Hydroxy-4-methoxybenzoic acid possesses antihyperlipidemic, antidiabetic and hepatoprotective activities.
-
MCT1-IN-3
0 ImagesMCT1-IN-3 is a monocarboxylate transporter 1 (MCT1) inhibitor with an IC50 value of 81.0 nM. MCT1-IN-3 has also significant inhibitivity against the multidrug transporter ABCB1. MCT1-IN-3 can be used for the research of cancer.
-
H-HoArg-OH-d4
0 ImagesCat. No.: HY-W008385SCAS No.: 1332075-41-8Synonyms: L-Homoarginine-d4H-HoArg-OH-d4 (L-Homoarginine-d4) is the d4-labeled H-HoArg-OH (HY-W008385). H-HoArg-OH (L-Homoarginine) is an orally active endogenous non-protein amino acid. H-HoArg-OH acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y+-type transporters (system y+). H-HoArg-OH increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HoArg-OH can be used in studies related to diabetes and cardiomyopathy.
-
AR-C141990 hydrochloride
0 ImagesAR-C141990 hydrochloride is a potent lactate transporters (monocarboxylate transporters; MCTs) inhibitor with pKi values of 7.6, 6.6 for MCT-1 and MCT-2, respectively. AR-C141990 hydrochloride has immunosuppressive properties and inhibits graft versus host response.
-
H-HoArg-OH-d4 dihydrochloride
0 ImagesCat. No.: HY-W008385ASSynonyms: L-Homoarginine-d4 dihydrochlorideH-HoArg-OH-d4 dihydrochloride (L-Homoarginine-d4 dihydrochloride) is the d4-labeled H-HoArg-OH dihydrochloride. H-HoArg-OH dihydrochloride (L-Homoarginine dihydrochloride) is an orally active endogenous non-protein amino acid. H-HoArg-OH dihydrochloride acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y+-type transporters (system y+). H-HoArg-OH dihydrochloride increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HoArg-OH dihydrochloride can be used in studies related to diabetes and cardiomyopathy.
-
H-HoArg-OH (Standard)
0 ImagesSynonyms: L-Homoarginine (Standard)H-HoArg-OH (Standard) (L-Homoarginine (Standard)) is the analytical standard of H-HoArg-OH (HY-W008385). This product is intended for research and analytical applications. H-HomoArg-OH (L-Homoarginine) is an orally active endogenous non-protein amino acid. H-HomoArg-OH acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y+-type transporters (system y+). H-HomoArg-OH increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HomoArg-OH can be used in studies related to diabetes and cardiomyopathy.
-
slCeMM1
0 ImagesCat. No.: HY-182416CAS No.: 949973-22-2slCeMM1 is a selective SLC16A3 (MCT4) inhibitor. slCeMM1 inhibits lactate transport, induces intracellular lactate accumulation, reduces viability of SLC16A3-dependent cells, and inhibits growth of SLC16A3-dependent cells. slCeMM1 can be used for the research of rheumatoid arthritis and cancer.
-
AR-C141990
0 ImagesCat. No.: HY-119996CAS No.: 873327-59-4AR-C141990 (Compound 30) is a potent blocker of the monocarboxylate transporter MCT1 with a Ki of 4.8 nM. AR-C141990 (Compound 30) inhibits CYP3A4 and CYP2C9 with IC50 values of 16 μM.
-
PEG9MA10-PAB10-GalMA10
0 ImagesCat. No.: HY-184926PEG9MA10-PAB10-GalMA10 is a CD147 LYTAC degrader. PEG9MA10-PAB10-GalMA10 binds to the asialoglycoprotein receptor (ASGPR) via its galactose methacrylate domain, mediating its uptake by hepatoma cells. PEG9MA10-PAB10-GalMA10 induces lysosome-dependent degradation of CD147, resulting in concurrent loss of associated MCT1 and MCT4. PEG9MA10-PAB10-GalMA10 reduces extracellular lactate levels, increases intracellular lactate accumulation, inhibits glycolytic activity, and enhances mitochondrial respiratory capacity. PEG9MA10-PAB10-GalMA10 decreases the secretion of MMP-2 and MMP-9, and upregulates the expression of E-cadherin. PEG9MA10-PAB10-GalMA10 exhibits anti-tumor efficacy in hepatoma models. PEG9MA10-PAB10-GalMA10 can be used for research on liver cancer (hepatocellular carcinoma).
-
α-Cyano-4-hydroxycinnamic acid-d4
0 ImagesCat. No.: HY-107641SCAS No.: 1258536-45-6Synonyms: α-Cyano-4-hydroxycinnamate-d4α-Cyano-4-hydroxycinnamic acid-d4 (α-Cyano-4-hydroxycinnamate-d4) is the deuterium labeled α-Cyano-4-hydroxycinnamic acid (HY-107641). α-Cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamate) is a potent and non-competitive inhibitor of monocarboxylate transporters (MCTs). α-Cyano-4-hydroxycinnamic acid inhibits mitochondrial pyruvate transporter with a Ki of 6.3 μM. α-Cyano-4-hydroxycinnamic acid is used as a matrix to facilitate peptide ionization in matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry applications.
-
Anti-MSR1 Antibody
0 ImagesCat. No.: HY-P992269
-
Anti-MCT1 Antibody
0 ImagesCat. No.: HY-P992265
-
Syrosingopine (Standard)
0 ImagesSyrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine.
-
Silychristin (Standard)
0 ImagesCat. No.: HY-N0647RCAS No.: 33889-69-9Silychristin (Standard) is the analytical standard of Silychristin. This product is intended for research and analytical applications. Silychristin is an abundant flavonolignan present in the fruits of Silybum marianum, with antioxidant properties. Silychristin is a potent inhibitor of the thyroid hormone transporter MCT8, and elicits a strong inhibition of T3 uptake with an IC50 of 110 nM.
-
MCT4-IN-2
0 ImagesCat. No.: HY-189476CAS No.: 2230187-60-5MCT4-IN-2 is an orally active monocarboxylate transporter MCT4 inhibitor. MCT4-IN-2 inhibits the activity of MCT4. MCT4-IN-2 can be used for the research of inflammatory diseases, proliferative diseases and pulmonary fibrosis.
-
H-HomoArg-OH hydrochloride (Standard)
0 ImagesCat. No.: HY-W012340RCAS No.: 1483-01-8H-HomoArg-OH hydrochloride (Standard) is the analytical standard of H-HomoArg-OH hydrochloride (HY-W012340). This product is intended for research and analytical applications. H-HomoArg-OH hydrochloride (L-Homoarginine hydrochloride) is an orally active endogenous non-protein amino acid. H-HomoArg-OH hydrochloride acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y+-type transporters (system y+). H-HomoArg-OH hydrochloride increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HomoArg-OH hydrochloride can be used in studies related to diabetes and cardiomyopathy.
-
AR-C117977
0 ImagesCat. No.: HY-114602CAS No.: 216685-07-3AR-C117977 is a potent monocarboxylate transporter (MCT1) inhibitor. AR-C117977 prolongs the survival of skin and heart sllograft. AR-C117977 inhibits the development of transplant arteriosclerosis in aortic allografts partially, but was unable to inhibit alloantibody production after transplantation. AR-C117977 shows potent immunosuppressive properties in vivo effectively preventing acute but not chronic allograft rejection in the mouse.
-
Lactate transportor 1
0 ImagesCat. No.: HY-155382Lactate transportor 1 (compound 1) is an active lactate transporter in living cells. Lactate transportor 1 displays the cytotoxic effect, with IC50 values of 3.36, 3.27,5.58 and 7.66 μM in Hela, CAL27, MCF7 and MCF10A, respectively. Lactate transportor 1 has an additive effect with Cisplatin (HY-17394) observed in HeLa cells.
-
D-2-Phosphoglyceric acid
0 ImagesCat. No.: HY-128736BCAS No.: 3443-57-0D-2-Phosphoglyceric acid is an intermediate product of glycolysis and gluconeogenesis, and its level changes are associated with the glycolysis pathway regulated by MCT4. The intracellular level of D-2-Phosphoglyceric acid decreases in hypoxic glioblastoma stem cells after MCT4 knockdown. D-2-Phosphoglyceric acid can be used in the research of glioblastoma.
